Global

Recent News Releases

CSL Behring News Releases

CSL Behring Subscribe to alerts

CSL Limited Financial News

23 June 2017
FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema
Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients. More.

19 May 2017
New Innovation in the Fight Against Hemophilia Earns CSL Behring the NORD 2017 Industry Innovation Award
CSL Behring received the National Organization for Rare Disorders’ (NORD) 2017 Industry Innovation Award last night in Washington, D.C. for pioneering new medicines. More.

19 April 2017
Therapeutic Goods Administration Approves AFSTYLA® - CSL Behring’s Novel Recombinant Haemophilia A Treatment
Global biotherapeutics leader, CSL Behring today announced that the Australian Therapeutic Goods Administration (TGA) has approved AFSTYLA® [lonoctocog alfa]. More.

Media Resources

CSL Behring Company Information CSL Behring
Company Information >
CSL Behring Media Contacts CSL Behring
Media Contacts >
CSL Behring Social Media CSL Behring
Social Media >
CSL Behring MultiMedia Library CSL Behring
Images and Videos >



Our Patients' Stories




CSL Behring at a Glance

CSL Behring at a glance







Share
LinkedIn Twitter Facebook Google+